Found: 139
Select item for more details and to access through your institution.
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1511, doi. 10.1007/s10637-011-9693-6
- By:
- Publication type:
- Article
Reversible posterior leukoencephalopathy syndrome and trastuzumab.
- Published in:
- 2012
- By:
- Publication type:
- Report
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 844, doi. 10.1007/s10637-009-9321-x
- By:
- Publication type:
- Article
Nivolumab-induced interstitial lung disease in a patient with gastric cancer.
- Published in:
- Oxford Medical Case Reports, 2019, v. 2019, n. 2, p. N.PAG, doi. 10.1093/omcr/omz007
- By:
- Publication type:
- Article
BRAF<sup>V600E</sup> inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
- Published in:
- Scientific Reports, 2016, p. 18949, doi. 10.1038/srep18949
- By:
- Publication type:
- Article
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
- Published in:
- International Journal of Cancer, 2006, v. 118, n. 4, p. 812, doi. 10.1002/ijc.21350
- By:
- Publication type:
- Article
Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
- Published in:
- Digestive Surgery, 2017, v. 35, n. 1, p. 70, doi. 10.1159/000475477
- By:
- Publication type:
- Article
Front Cover: A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma (ChemMedChem 15/2019).
- Published in:
- ChemMedChem, 2019, v. 14, n. 15, p. 1377, doi. 10.1002/cmdc.201900435
- By:
- Publication type:
- Article
A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
- Published in:
- ChemMedChem, 2019, v. 14, n. 15, p. 1384, doi. 10.1002/cmdc.201900324
- By:
- Publication type:
- Article
Convolutional Neural Network Can Recognize Drug Resistance of Single Cancer Cells.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 9, p. 3166, doi. 10.3390/ijms21093166
- By:
- Publication type:
- Article
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.
- Published in:
- International Journal of Colorectal Disease, 2021, v. 36, n. 12, p. 2621, doi. 10.1007/s00384-021-04002-9
- By:
- Publication type:
- Article
Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107).
- Published in:
- Gastrointestinal Tumors, 2022, v. 9, n. 1, p. 27, doi. 10.1159/000522610
- By:
- Publication type:
- Article
Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality.
- Published in:
- International Journal of Oncology, 2024, v. 65, n. 1, p. N.PAG, doi. 10.3892/ijo.2024.5662
- By:
- Publication type:
- Article
The epitranscriptome m<sup>6</sup>A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.
- Published in:
- International Journal of Oncology, 2018, v. 52, n. 2, p. 621, doi. 10.3892/ijo.2017.4219
- By:
- Publication type:
- Article
Hypoxia stimulates the cytoplasmic localization of oncogenic long noncoding RNA LINC00152 in colorectal cancer.
- Published in:
- International Journal of Oncology, 2018, v. 52, n. 2, p. 453, doi. 10.3892/ijo.2017.4218
- By:
- Publication type:
- Article
The one-carbon metabolism pathway highlights therapeutic targets for gastrointestinal cancer (Review).
- Published in:
- International Journal of Oncology, 2017, v. 50, n. 4, p. 1057, doi. 10.3892/ijo.2017.3885
- By:
- Publication type:
- Article
ASO Visual Abstract: Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival in Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.
- Published in:
- 2023
- By:
- Publication type:
- Abstract
Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2023, v. 30, n. 9, p. 5899, doi. 10.1245/s10434-023-13548-7
- By:
- Publication type:
- Article
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2019, v. 26, n. 13, p. 4754, doi. 10.1245/s10434-019-07744-7
- By:
- Publication type:
- Article
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
- Published in:
- British Journal of Cancer, 2022, v. 126, n. 11, p. 1555, doi. 10.1038/s41416-022-01726-5
- By:
- Publication type:
- Article
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 5, p. 788, doi. 10.1007/s10120-023-01408-y
- By:
- Publication type:
- Article
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 207, doi. 10.1007/s10120-021-01230-4
- By:
- Publication type:
- Article
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
- Published in:
- Gastric Cancer, 2021, v. 24, n. 4, p. 946, doi. 10.1007/s10120-021-01173-w
- By:
- Publication type:
- Article
Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study.
- Published in:
- Gastric Cancer, 2021, v. 24, n. 3, p. 701, doi. 10.1007/s10120-020-01137-6
- By:
- Publication type:
- Article
Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3).
- Published in:
- Gastric Cancer, 2021, v. 24, n. 2, p. 428, doi. 10.1007/s10120-020-01112-1
- By:
- Publication type:
- Article
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
- Published in:
- Gastric Cancer, 2020, v. 23, n. 3, p. 510, doi. 10.1007/s10120-019-01034-7
- By:
- Publication type:
- Article
Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
- Published in:
- Gastric Cancer, 2020, v. 23, n. 3, p. 520, doi. 10.1007/s10120-019-01023-w
- By:
- Publication type:
- Article
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
- Published in:
- Gastric Cancer, 2020, v. 23, n. 1, p. 143, doi. 10.1007/s10120-019-00970-8
- By:
- Publication type:
- Article
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
- Published in:
- Gastric Cancer, 2019, v. 22, n. 4, p. 817, doi. 10.1007/s10120-018-0903-1
- By:
- Publication type:
- Article
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
- Published in:
- Gastric Cancer, 2019, v. 22, n. 2, p. 344, doi. 10.1007/s10120-018-0899-6
- By:
- Publication type:
- Article
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
- Published in:
- Gastric Cancer, 2018, v. 21, n. 6, p. 1041, doi. 10.1007/s10120-018-0811-4
- By:
- Publication type:
- Article
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
- Published in:
- Gastric Cancer, 2018, v. 21, n. 3, p. 429, doi. 10.1007/s10120-017-0773-y
- By:
- Publication type:
- Article
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.
- Published in:
- Gastric Cancer, 2015, v. 18, n. 4, p. 824, doi. 10.1007/s10120-014-0420-9
- By:
- Publication type:
- Article
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
- Published in:
- Gastric Cancer, 2013, v. 16, n. 2, p. 175, doi. 10.1007/s10120-012-0167-0
- By:
- Publication type:
- Article
Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
- Published in:
- 2013
- By:
- Publication type:
- Correction notice
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
- Published in:
- Gastric Cancer, 2012, v. 15, n. 3, p. 313, doi. 10.1007/s10120-011-0118-1
- By:
- Publication type:
- Article
A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer.
- Published in:
- Oncology, 2019, v. 97, n. 4, p. 211, doi. 10.1159/000500677
- By:
- Publication type:
- Article
Cell‑free culture conditioned medium elicits pancreatic β cell lineage‑specific epigenetic reprogramming in mice.
- Published in:
- Oncology Letters, 2018, v. 16, n. 3, p. 3255, doi. 10.3892/ol.2018.9008
- By:
- Publication type:
- Article
c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer.
- Published in:
- Oncology Letters, 2018, v. 16, n. 2, p. 1892, doi. 10.3892/ol.2018.8793
- By:
- Publication type:
- Article
The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer.
- Published in:
- Oncology Letters, 2018, v. 16, n. 2, p. 1827, doi. 10.3892/ol.2018.8795
- By:
- Publication type:
- Article
Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer.
- Published in:
- Oncology Letters, 2018, v. 15, n. 5, p. 8125, doi. 10.3892/ol.2018.8357
- By:
- Publication type:
- Article
Adipose-derived mesenchymal stem cells and regenerative medicine.
- Published in:
- Development, Growth & Differentiation, 2013, v. 55, n. 3, p. 309, doi. 10.1111/dgd.12049
- By:
- Publication type:
- Article
Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 9, p. 1237, doi. 10.1007/s10147-024-02500-8
- By:
- Publication type:
- Article
Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902).
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 2, p. 134, doi. 10.1007/s10147-023-02437-4
- By:
- Publication type:
- Article
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 11, p. 1501, doi. 10.1007/s10147-023-02402-1
- By:
- Publication type:
- Article
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106).
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 9, p. 1176, doi. 10.1007/s10147-023-02376-0
- By:
- Publication type:
- Article